Advertisement
Advertisement

PDSB

PDSB logo

PDS Biotechnology Corporation Common Stock

1.25
USD
Sponsored
+0.11
+9.65%
May 08, 16:00 UTC -4
Closed
exchange

After-Market

1.26

+0.01
+0.48%

PDS Biotechnology Corporation Common Stock Profile

About

PDS Biotechnology Corp. is an immuno-oncology company. It is focused on developing a pipeline of clinical-stage immunotherapies to treat cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, cancer and other cancers. The company's products are based on the proprietary Versamune(R) platform technology, which activates and directs the human immune system. PDS Biotechnology Corp, formerly known as Edge Therapeutics Inc., is based in Berkeley Heights, United States.

Info & Links

CEO

Frank Bedu-Addo

Headquarters

303A College Road
East Princeton, NJ 08540, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.pdsbiotech.com

Auditor

KPMG LLP

Share holders

35

Employees

21

PDS Biotechnology Corporation Common Stock Statistics

Valuation Measures

Market Capitalization2

70.10M

Enterprise Value

60.32M

Enterprise Value/EBITDA(ttm)

-2.02

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

6.06

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-241.95%

Return on Invested Capital(ttm)

-140.25%

Return on Assets(ttm)

-90.36%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-29.93M

Net Income Available to Common(ttm)

-34.50M

Diluted EPS(ttm)

-0.75

Share Statistics

Beta (5Y Monthly)

1.20

52-Week Change

2.46%

S&P 500 52-Week Change

26.60%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

55.82M

Dividend Yield

0.00%

Float4

50.68M

% Held by Insiders

9.20%

% Held by Institutions

26.84%

Balance Sheet

Total Cash(mrq)

26.71M

Total Cash Per Share(mrq)

0.48

Total Debt(mrq)

16.93M

Total Debt/Equity(mrq)

182.94%

Current Ratio(mrq)

2.98%

Quick Ratio(mrq)

2.98%

Book Value Per Share(mrq)

0.17

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.60

Free Cash Flow(ytd)

-27.75M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement